Edwards Lifesciences (EW) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Edwards Lifesciences (NYSE: EW):

• 4/27/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Barclays PLC. They now have a $110.00 price target on the stock, up from $104.00.
• 4/24/2026 – Edwards Lifesciences was given a new $90.00 price target by Truist Financial Corporation. They now have a “hold” rating on the stock.
• 4/24/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $93.00 price target on the stock.
• 4/24/2026 – Edwards Lifesciences was given a new $85.00 price target by Canaccord Genuity Group Inc.. They now have a “hold” rating on the stock.
• 4/24/2026 – Edwards Lifesciences had its price target raised by Robert W. Baird from $85.00 to $87.00. They now have a “neutral” rating on the stock.
• 4/24/2026 – Edwards Lifesciences had its price target raised by BTIG Research from $98.00 to $100.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 4/13/2026 – Edwards Lifesciences was given a new $95.00 price target by Mizuho. They now have an “outperform” rating on the stock.
• 4/1/2026 – Edwards Lifesciences was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $92.00 price target on the stock.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $83.98, for a total transaction of $85,575.62. Following the sale, the vice president directly owned 33,682 shares in the company, valued at $2,828,614.36. This trade represents a 2.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 88,096 shares of company stock valued at $7,288,799 over the last three months. 0.31% of the stock is owned by insiders.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.